Mantle Cell Lymphoma (MCL) Recruiting Phase 2 Trials for Rituximab (DB00073)

Also known as: Mantle Cell Lymphomas / Lymphoma, Mantle-Cell / Mantle-Cell Lymphoma / Lymphoma, Mantle Cell / Mantle Cell Lymphoma / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS

IndicationStatusPhase
DBCOND0071979 (Mantle Cell Lymphoma (MCL))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03834688Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of AgeTreatment
NCT04115631A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell LymphomaTreatment
NCT03863184Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCLTreatment
NCT03710772Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell LymphomaTreatment
NCT03019640Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's LymphomaTreatment
NCT02339922Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin LymphomaTreatment
NCT01880567Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell LymphomaTreatment